SARS-CoV-2 nsp4 Antibody [DyLight 650]

• Reactivity: V
• Applications: ELISA
• Clonality: Polyclonal
• Host: Rabbit
• Conjugate: DyLight 650

SARS-CoV-2 nsp4 Antibody [DyLight 650] Summary

• Immunogen: This antibody was raised against a peptide corresponding to 15 amino acids near the center of SARS-CoV-2 (COVID-19) NSP4 protein. The immunogen is located within 50-100 amino acids of the SARS-CoV-2 (COVID-19) NSP4 protein.
• Isotype: IgG
• Clonality: Polyclonal
• Host: Rabbit
• Gene: ORF1ab
• Purity: Peptide affinity purified

Applications/Dilutions

• Dilutions:
  • ELISA
• Application Notes: Optimal dilution of this antibody should be experimentally determined.

Reactivity Notes

Predicted reactivity based on immunogen sequence: SARS-CoV NSP4 protein: (85%)

Packaging, Storage & Formulations

• Storage: Store at 4C in the dark.
• Buffer: 50mM Sodium Borate
• Preservative: 0.05% Sodium Azide
• Purity: Peptide affinity purified

Notes

DyLight (R) is a trademark of Thermo Fisher Scientific Inc. and its subsidiaries.

Alternate Names for SARS-CoV-2 nsp4 Antibody [DyLight 650]

• Corona_NSP4_C
• Coronavirus nonstructural protein 4 C-terminus
• Non-structural protein 4
• nsp4

Background

SARS-CoV-2 Nonstructural Protein 4 (NSP4) is one of the sixteen nonstructural proteins of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the causative agent of COVID-19 (1). SARS-CoV-2 NSP4 is 500 amino acids (aa) with a theoretical molecular weight of 56.2 kDa (1,2). The amino acid sequence alignment of SARS-CoV and SARS-CoV-2's NSP4 has 80% sequence identity and 95% sequence similarity (1). Structurally, SARS-CoV-2 NSP4 protein has four transmembrane domains (3). SARS-CoV-2 interactome studies revealed that NSP4 interacts with the TIM (translocase of the inner membrane) complex, indicating an association with the mitochondria (2). Additionally, SARS-CoV-2 NSP4 is shown to interact with NSP3 and this interaction is required for viral replication (1). Specifically, the NSP3-NSP4 interaction is responsible for double membrane vesicle formation (3).

References

1. Yoshimoto F. K. (2020). The Proteins of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS CoV-2 or n-COV19), the Cause of COVID-19. The Protein Journal. https://doi.org/10.1007/s10930-020-09901-4

2. Gordon, D. E., Jang, G. M., Bouhaddou, M., Xu, J., Obernier, K., White, K. M., O'Meara, M. J., Rezelj, V. V., Guo, J. Z., Swaney, D. L., Tummino, T. A., Huttenhain, R., Kaake, R. M., Richards, A. L., Tutuncuoglu, B., Foussard, H., Batra, J., Haas, K., Modak, M., Kim, M., ... Krogan, N. J. (2020). A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. Nature. https://doi.org/10.1038/s41586-020-2286-9

3. Qiu, Y., & Xu, K. (2020). Functional studies of the coronavirus nonstructural proteins. STEMedicine. https://doi.org/10.37175/stemedicine.v1i2.39

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Bioinformatics

• Gene Symbol: ORF1ab